

# POTENTIAL MECHANISMS OF ACTION OF VITAMIN D AFFECTING SARS-COV-2

Milana Vuković<sup>1</sup>, Jelena Jovičić Bata<sup>1</sup>, Mladena Lalić Popović<sup>1</sup>, Nemanja Todorović<sup>1</sup>, Jelena Čanji Panić<sup>1</sup>, Dunja Vesković<sup>2</sup>

<sup>1</sup>Department of Pharmacy, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia

<sup>2</sup>Clinic for Dermatovenereology Diseases, Clinical Center of Vojvodina, Novi Sad, Serbia

## INTRODUCTION

Since the outbreak of the pandemic, vit D has been in focus as a potential molecule for prevention and treatment of COVID-19.

## METHOD/DESIGN

- PubMed and Google Scholar (2020 and 2021)
- ClinicalTrials.gov: "COVID-19" and "vitamin D" (October 13, 2021)

## OBJECTIVES



- present the potential mechanisms of action of vit D that were reported as potentially beneficial against SARS-CoV-2
- identify ongoing clinical trials regarding COVID-19 and vit D

## RESULTS

Vit D ↑ cathelicidin and β-defensin 2 (antimicrobial and antiviral peptides)

Vit D ↓ IL-6, IL-8, IL-12, TNF, INF-γ and IL-17

- COVID-19 infection down-regulates ACE2, which in turn could lead to excessive accumulation of angiotensin II
- vit D induces expression of ACE2 in the lungs in experimental animals in specific experimental conditions. ACE2 thus expressed more as a consequence of vit D supplementation might reduce lung injury
- although vit D increases the expression of ACE2, which indeed promotes the binding of the virus, it prevents pulmonary vasoconstriction response in COVID-19 cases
- ACE2 has potentially contradictory roles. On one hand, greater expression of it would be assumed as a potential risk since it is the receptor for SARS-CoV-2, but on the other, it has an important protecting role against acute lung injury and ARDS in experimental models



Vitamin D molecule, source: www.3dchem.com

**Mentioned mechanisms of action are still an area of research and need to be clinically confirmed.**

**110 clinical trials regarding vit D and COVID-19 were registered in the ClinicalTrials.gov registry**

Status	Type
72 active/not yet started	78 interventional
32 completed	32 observational

## CONCLUSION

As the exact molecular mechanisms are being clarified, new clinical trials are designed in order to confirm the link between vit D deficiency and COVID-19 severity and the potential benefits of vit D administration for prevention and treatment of COVID-19.